Questions for BNC Good morning, Jennifer,
What a big surprise! Please clarify the following for me:
1. With the sale of the Animal Health unit, am I correct to presume we would include Sin Susto, Immnocidin and Oncocidin?
2. If we do, who owns the manufacturing rights to these products?
3. If the buyer will manufacture these products, are they going to buy the facilities that are required for the manufacturing?
4.Since Immunocidin and Oncocidin are both related and a derivative of the MCC platform, what are we doing with the patent of the MCC platform?
5. Are we selling the platform?
6. If we are retaining the rights on the MCC technology, shall we be making the Immunocidin and Oncocidin for them?
7. If #6 were true, are we going to receive royalty from these products? Or are we going to make these products and be a supplier for the buyer?
8. Same goes with Sin Susto. We have the global selling right, what are we doing with this right?
Finally, but not the least importantly,
9. What does BNC plan to do with the proceeds?
10. In the RPC loan document, it says that the loan is due if there is a change of management. Does that mean the loan is called and we shall pay it up immediately?
11. In this scenario, is there a "pre-payment" penalty to this loan?
Thanks for our attention. I am looking forward for your reply.
Dr. XXXXX